Bladder cancer (BC) is the 10th most common cancer world-wide with an estimated 570,000+ people being diagnosed in 2020. The incidence, attributed morbidity and high treatment costs makes BC an important area of further research to improve therapies and patient quality of life. BCG is still one of the most successful cancer immunotherapies used as a standard therapy for high-risk NMIC. However, despite its anti-tumour efficacy, half of the patients eventually develop tumour recurrence, with 30% progressing to muscle invasive disease.
As the clinical outcome of cancer patients is highly dependent on the state of the tumour microenvironment (TME) there is considerable interest in understanding the role of the tumour immune microenvironment in disease progression in NMIBC and the mechanisms of resistance to BCG immunotherapy. The webinar will discuss the integrated use of pan-cancer gene expression analysis with Akoya Bioscience’s multiplexed immunofluorescence workflow on NMIBC FFPE tissues to find a predictive biomarker panel capable of stratifying patients who will benefit from BCG immunotherapy and to identify new targets for further investigation of therapeutic strategies for BCG-unresponsive tumours.
Related Posts
Accelerate Building Custom Spatial Proteomic Panels for New Biological Insights
Ultrasensitive Neuroimmune Biomarker Measurement for Translational Research and Therapeutic Development
Underdiagnosis of Alzheimer’s disease pathology in patients with cardiovascular disease
Decoding Neurodegeneration: High-plex Spatial Proteomics Reveal Distinct Cell Phenotypes and Pathological Signatures in Parkinson’s and Alzheimer’s Disease
In this webinar, Dr. Birgitt Schuele, Associate Professor (Research) of Pathology at Stanford University, showcases how ultrahigh-plex spatial proteomics is being used to uncover distinct cell phenotypes and pathological signatures…
Understanding the Brain: Advancing Neurodegeneration Research with Ultrahigh-Plex Spatial Proteomics
In this webinar, learn how ultrahigh-plex spatial phenotyping has been applied to neurodegenerative disease research.
p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
Spatial Awareness: AI-powered Profiling of Trillions of Immune Cell Distribution Data Points Reveals Key Predictors of Cancer Recurrence Risk
This webinar highlights a groundbreaking study recently published as a Nature cover story (April 2025). Dr. Joe Yeong will describe how a pre-designed analytical framework—driven by well-defined clinical and scientific…
Multimodal Single-Cell Spatial Transcriptomics and Proteomics to Uncover the Biological Processes Driving Immunotherapy Response and Resistance in Renal Cancer
In this webinar, Dr. Anne-Laure Cattin from the Cancer Dynamics Laboratory at The Francis Crick Institute in London, will share her research on kidney cancer, focusing on the integration of…